Comparative Pharmacology
Head-to-head clinical analysis: ACETOHEXAMIDE versus DIABINESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETOHEXAMIDE versus DIABINESE.
ACETOHEXAMIDE vs DIABINESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin release from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels (K_ATP), causing membrane depolarization, calcium influx, and exocytosis of insulin-containing granules. Also may increase peripheral insulin sensitivity.
Sulfonylurea that stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to cell depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
Initial: 250 mg orally once daily; maintenance: 250-1500 mg orally once daily or in divided doses twice daily.
Initial: 250 mg orally once daily, increase by 125-250 mg every 1-2 weeks as needed. Maintenance: 100-500 mg once daily. Maximum: 750 mg daily.
None Documented
None Documented
Terminal elimination half-life: 6-12 hours (parent drug); ~5-6 hours (active metabolite hydroxyhexamide); clinical context: prolonged in renal impairment due to accumulation of active metabolite
Terminal elimination half-life 25–36 hours; in renal impairment, half-life prolonged significantly.
Renal: 85-90% (60-70% as unchanged drug, remainder as hydroxylated metabolite); biliary/fecal: <10%
Primarily renal (up to 80% unchanged); minor fecal (biliary) excretion (<10%).
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic